Stock Ticker

  • Loading stock data...

Forest Laboratories, Inc. (NYSE:FRX): Consolidation Over GI Business

Boston, MA 05/01/2014 (wallstreetpr) – Pharma industry is going through consolidation about their core business and Forest Laboratories, Inc. (NYSE:FRX) is of no exception that enters into an agreement to acquire Furiex for its gastrointestinal (GI) business. Deal agreement Forest Laboratories, Inc. (NYSE:FRX) will acquire Furiex for $125 per share (~ $1.5 billion), including cash and […]

Top Three Trending Stocks: Alpha Natural Resources, Inc. (NYSE:ANR), Forest Laboratories, Inc. (NYSE:FRX), Eli Lilly & Co. (NYSE:LLY)

Boston, MA 02/20/2014 (wallstreetpr) – Alpha Natural Resources, Inc. (NYSE:ANR) last week had its stock price objective and rating by several investment analysts and brokerages tracking the company. Analysts at Barclays lowered their price target on the stock to $6 from $7 and planted and “equal-weight” rating. The stock also had its rating updated by JPMorgan […]

Hot Picks: NCI Inc. (NASDAQ:NCIT), Forest Laboratories, Inc. (NYSE:FRX) & Lightbridge Corp (NASDAQ:LTBR)

Boston, MA 02/18/2014 (wallstreetpr) – NCI Inc. (NASDAQ:NCIT) posts strong fourth quarter results NCI Inc. (NASDAQ:NCIT) a leading provider of information technology, professional services and solutions to the US federal government posted strong fourth quarter results for the period ending December 31, 2013. Fourth quarter revenue camein at $80 million exceeding a guidance of $7 […]

Forest Laboratories, Inc. (NYSE:FRX): Latest Acquisition to Add $700 in Revenue

Boston, MA 01/09/2013 (wallstreetpr) – Drugmaker Forest Laboratories, Inc. (NYSE:FRX) is investing $2.9 billion to acquire pharmaceutical firm Aptalis. This is the company’s first major acquisition in 2014 and a lot of hopes are tied to it as regards the growth of FRX. Following this acquisition, the drug maker expects to boost its revenue by […]